Developer docs
API playgroundTry for free, no card

Search company profiles

RG Discovery

Full company profile

uuid000oj41

Namestring
RG Discovery
Legal namestring
RG Discovery AB
Websiteurl
rgdiscovery.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

RG Discovery (formerly Red Glead Discovery, rebranded January 2025) is a Scandinavian contract research organization founded in 2011 by seven former AstraZeneca scientists in Lund, Sweden, and acquired by Pelago Bioscience in June 2026. The company delivers integrated drug discovery services spanning medicinal chemistry, in vitro biology and screening, ADME and bioanalysis, fragment-based lead discovery, NMR spectroscopy, computational chemistry, analytical chemistry and custom synthesis, peptide chemistry, and macrocyclic peptides, with particular depth in small molecules, peptides, and macrocyclic scaffolds. Its core technology platform is co-located in a single building at Medicon Village, enabling seamless handoffs across the design-make-test-analyze cycle, and includes proprietary WAC (Weak Affinity Chromatography) fragment screening technology held jointly with SARomics Biostructures. The business operates a sales-led, B2B model offering both FTE-based contract research and fee-for-service engagements to early- to mid-stage biotech, large pharmaceutical companies, and academic institutions across Europe, the US, and the Nordics. By the time of acquisition, RG Discovery employed roughly 40-60 scientists (with 95% of staff in lab or science-based roles), had served 250+ clients since inception, generated 95% of sales from returning customers, and reported 33% average annual revenue growth over the three years ending 2022, with SEK 44M in revenue in 2020.

Short descriptiontext

RG Discovery is a Scandinavian CRO providing integrated small-molecule, peptide, and macrocyclic drug discovery services, including proprietary WAC fragment screening, to biotech and pharma clients globally from its single-site Lund facility.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, drug discovery, medicinal chemistry, custom synthesis, fragment screening
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research / Drug Discovery Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services (FTE-based)
TypeProfessional Services
Description

Full-time equivalent staffing model where dedicated chemists and scientists work on client projects on an ongoing basis.

rgdiscovery.com
2Fee-for-Service
TypeProfessional Services
Description

Specific service engagements billed per project or deliverable basis for various drug discovery activities.

rgdiscovery.com
3Custom Synthesis
TypeProfessional Services
Description

Synthesis of small molecules, peptides, macrocycles, carbohydrates, radioligands, conjugates & linkers, and polymers for pharmaceutical clients.

rgdiscovery.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RG Discovery is a Scandinavian contract research organization (CRO) providing premium integrated drug discovery, analysis, and custom synthesis services. The company delivers medicinal chemistry, in vitro biology/assays, ADME profiling, fragment-based lead discovery, NMR spectroscopy, computational chemistry, custom synthesis, and peptide/macrocyclic peptide services to biotechnology and pharmaceutical clients globally, with deep expertise in small molecules, peptides, and macrocycles. Services are sold via FTE-based staffing and fee-for-service engagements and supported by the proprietary WAC™ (Weak Affinity Chromatography) fragment screening platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 95% sales from returning customers
+3 more records
Product overview1 text field

RG Discovery is a Scandinavian contract research organization (CRO) providing integrated drug discovery services. The company operates a unified platform combining multiple service areas: Medicinal Chemistry, In Vitro Biology/Assays & Screening, ADME & Bioanalysis, Fragment-Based Lead Discovery (FBLD), NMR Spectroscopy, Computational Chemistry, Analytical Chemistry & Separation, Custom Synthesis, Peptide Chemistry, and Macrocyclic Peptides. These services are delivered through an integrated approach enabling seamless workflows from hit identification through lead optimization. The platform also includes proprietary WAC™ (Weak Affinity Chromatography) technology for fragment screening. Services span small molecules, peptides, and macrocycles for biotechnology and pharmaceutical customers.

Product and service6 records
1Medicinal Chemistry Services
CategoryDrug Discovery Services
Description

Comprehensive medicinal chemistry services driving projects from potential targets to patentable lead compounds and clinical candidates, with expertise spanning carbohydrate chemistry, nucleotide chemistry, organometallic chemistry, and heterocyclic chemistry. Sold to biotechnology and pharmaceutical clients.

2In Vitro Biology / Assays & Screening
CategoryDrug Discovery Services
Description

Biochemical and cell-based screening assays for target efficacy evaluation, including biochemical assays (luminescence, absorbance, fluorescence), binding assays, activity assays, and phenotypic screening using EnVision® Multilabel Plate Reader. Sold to biotech and pharma clients.

3ADME & Bioanalysis
CategoryDrug Discovery Services
Description

Lab services analyzing compound characteristics including physicochemical assays (solubility, lipophilicity, PAMPA, EPSA), metabolic stability, plasma protein binding, and pharmacokinetic study support.

4Fragment-Based Lead Discovery (FBLD)
CategoryDrug Discovery Services
Description

Integrated fragment screening platform in partnership with SARomics Biostructures using WAC™ technology, NMR, DSF, HCS, and crystallographic methods for hit identification and validation.

5NMR Spectroscopy Services
CategoryAnalytical & Custom Synthesis Services
Description

High-quality solution NMR services ranging from quality control to advanced structure elucidation, including structural analysis of organic molecules, macrocycles, natural products, peptides, and fragment screening using ligand-detected NMR techniques.

6Computational Chemistry
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Integrated fragment-based lead discovery partnership. RGD and SARomics Biostructures jointly operate the WAC fragment screening technology platform. Collaboration enables structure-based drug design throughout drug discovery phases.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint project Elbe funded by Vinnova to develop sustainable manufacturing process for GLP-1 peptide without using toxic solvent DMF. Both companies contribute green chemistry expertise.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Sognefjorden project: Eurostars-funded collaboration to deliver broad checkpoint inhibitor for cancer therapy. RGD contributes macrocycle/peptide drug molecule design and development.

4Desupervised
Strategic tierMajorTypeStrategic or Co-development Partner
Description

AId project: Eurostars-funded partnership to develop AI-based tool for drug discovery using Bayesian deep learning models for prediction of novel molecular structures.

rgdiscovery.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration on NMR-based structural elucidation of Zelenectide Pevedotin, a Bicycle Drug Conjugate for treatment of bladder, breast, and lung cancers.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

SSRI drug discovery research collaboration for novel selective serotonin reuptake inhibitors for combination treatment with Pimavanserin.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership to host startup competition and seminars on transforming research into drug development companies in Oslo, Norway.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration resulting in Nature Communications publication on CDNF neuroprotective activity and interaction with GRP78 protein.

9ApoGlyx
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Spinout company co-founded by RGD based on aquaporin research. RGD is co-owner. Developing RG100204 compound for sepsis treatment.

rgdiscovery.com
10Zerapeutics AB
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Company founded in 2021 from Project Nile (epigenetic target in cancer treatment) with candidate drug development supported by Vinnova.

rgdiscovery.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Scotland-based CRO offering integrated drug discovery, medicinal chemistry, and compound management services to biotech and pharma clients. Comparable scale and integrated DMTA-focused service model to RG Discovery.

TypeBroad incumbent
Description

Large global contract research and discovery company offering end-to-end drug discovery, including medicinal chemistry, ADME, in vitro biology, and fragment-based screening. Overlaps directly with RGD's offerings but at significantly greater scale and with broader service portfolio.

TypeDirect peer
Description

UK-based CRO providing integrated drug discovery including medicinal chemistry, in vitro pharmacology, ADME, and peptide chemistry. Closely comparable mid-size peer offering similar DMTA-cycle integrated services to biotech and pharma.

TypeBroad incumbent
Description

Global CRO providing discovery and safety assessment services, including medicinal chemistry, ADME, and integrated drug discovery for pharma and biotech. Much larger incumbent competing for the same outsourced discovery spend that RGD targets.

TypeBroad incumbent
Description

China/UK-headquartered CRO with integrated drug discovery and preclinical services including medicinal chemistry, in vitro biology, DMPK, and custom synthesis. Competes with RGD for biotech discovery outsourcing at much larger scale.

TypeDirect peer
Description

Swedish preclinical CRO and structural biology specialist; co-commercialises RGD's WAC fragment screening technology. Directly comparable as a Lund-based early-stage drug discovery CRO serving biotech clients with structural biology, fragment screening, and medicinal chemistry support.

TypeBroad incumbent
Description

Discovery services arm of Eurofins Scientific offering medicinal chemistry, ADME/PK, in vitro biology, and integrated drug discovery globally. Competes with RGD for outsourced preclinical discovery but at a much larger scale across a broader portfolio.

TypeDirect peer
Description

Swedish CRO specialising in CETSA-based target engagement assays and cell-based biology services; acquired RG Discovery in June 2026. Now part of the same combined entity, making it the most operationally overlapping peer and the platform onto which RGD's chemistry capabilities are being bolted.

TypeDirect peer
Description

UK-based preclinical CRO offering integrated drug discovery including medicinal chemistry, in vitro biology, DMPK, and computational chemistry for biotech and pharma clients. Closely comparable in scale and service mix to RG Discovery as a fully integrated chemistry-and-biology discovery CRO.

10Mercachem
TypeDirect peer
Description

Dutch CRO providing medicinal chemistry, custom synthesis, ADME, and parallel medicinal chemistry services to biotech and pharma. Closely comparable mid-size European peer focused on chemistry-driven integrated drug discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RG Discovery

Contract Research / Drug Discovery Servicesrgdiscovery.com

RG Discovery is a Scandinavian CRO providing integrated small-molecule, peptide, and macrocyclic drug discovery services, including proprietary WAC fragment screening, to biotech and pharma clients globally from its single-site Lund facility.

What RG Discovery does

RG Discovery (formerly Red Glead Discovery, rebranded January 2025) is a Scandinavian contract research organization founded in 2011 by seven former AstraZeneca scientists in Lund, Sweden, and acquired by Pelago Bioscience in June 2026. The company delivers integrated drug discovery services spanning medicinal chemistry, in vitro biology and screening, ADME and bioanalysis, fragment-based lead discovery, NMR spectroscopy, computational chemistry, analytical chemistry and custom synthesis, peptide chemistry, and macrocyclic peptides, with particular depth in small molecules, peptides, and macrocyclic scaffolds. Its core technology platform is co-located in a single building at Medicon Village, enabling seamless handoffs across the design-make-test-analyze cycle, and includes proprietary WAC (Weak Affinity Chromatography) fragment screening technology held jointly with SARomics Biostructures. The business operates a sales-led, B2B model offering both FTE-based contract research and fee-for-service engagements to early- to mid-stage biotech, large pharmaceutical companies, and academic institutions across Europe, the US, and the Nordics. By the time of acquisition, RG Discovery employed roughly 40-60 scientists (with 95% of staff in lab or science-based roles), had served 250+ clients since inception, generated 95% of sales from returning customers, and reported 33% average annual revenue growth over the three years ending 2022, with SEK 44M in revenue in 2020.

RG Discovery firmographics

Firmographics
Name
RG Discovery
Legal name
RG Discovery AB
Website
https://rgdiscovery.com
Company type
Private
Founded year
2011
Operating status
Acquired
Headcount range
11–50 employees
Short description
RG Discovery is a Scandinavian CRO providing integrated small-molecule, peptide, and macrocyclic drug discovery services, including proprietary WAC fragment screening, to biotech and pharma clients globally from its single-site Lund facility.
Ownership category
akta.pro rank

RG Discovery industry classification

Industry
Product category
Contract Research / Drug Discovery Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Contract research services
  • Drug discovery
  • Medicinal chemistry
  • Custom synthesis
  • Fragment screening

Where RG Discovery is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices3 records

Markets served

RG Discovery business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services (FTE-based): Full-time equivalent staffing model where dedicated chemists and scientists work on client projects on an ongoing basis.
  2. Fee-for-Service: Specific service engagements billed per project or deliverable basis for various drug discovery activities.
  3. Custom Synthesis: Synthesis of small molecules, peptides, macrocycles, carbohydrates, radioligands, conjugates & linkers, and polymers for pharmaceutical clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

RG Discovery product offering

Product offering

Core offering

RG Discovery is a Scandinavian contract research organization (CRO) providing premium integrated drug discovery, analysis, and custom synthesis services. The company delivers medicinal chemistry, in vitro biology/assays, ADME profiling, fragment-based lead discovery, NMR spectroscopy, computational chemistry, custom synthesis, and peptide/macrocyclic peptide services to biotechnology and pharmaceutical clients globally, with deep expertise in small molecules, peptides, and macrocycles. Services are sold via FTE-based staffing and fee-for-service engagements and supported by the proprietary WAC™ (Weak Affinity Chromatography) fragment screening platform.

Product overview

RG Discovery is a Scandinavian contract research organization (CRO) providing integrated drug discovery services. The company operates a unified platform combining multiple service areas: Medicinal Chemistry, In Vitro Biology/Assays & Screening, ADME & Bioanalysis, Fragment-Based Lead Discovery (FBLD), NMR Spectroscopy, Computational Chemistry, Analytical Chemistry & Separation, Custom Synthesis, Peptide Chemistry, and Macrocyclic Peptides. These services are delivered through an integrated approach enabling seamless workflows from hit identification through lead optimization. The platform also includes proprietary WAC™ (Weak Affinity Chromatography) technology for fragment screening. Services span small molecules, peptides, and macrocycles for biotechnology and pharmaceutical customers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medicinal Chemistry Services Comprehensive medicinal chemistry services driving projects from potential targets to patentable lead compounds and clinical candidates, with expertise spanning carbohydrate chemistry, nucleotide chemistry, organometallic chemistry, and heterocyclic chemistry. Sold to biotechnology and pharmaceutical clients.
  • In Vitro Biology / Assays & Screening Biochemical and cell-based screening assays for target efficacy evaluation, including biochemical assays (luminescence, absorbance, fluorescence), binding assays, activity assays, and phenotypic screening using EnVision® Multilabel Plate Reader. Sold to biotech and pharma clients.
  • ADME & Bioanalysis Lab services analyzing compound characteristics including physicochemical assays (solubility, lipophilicity, PAMPA, EPSA), metabolic stability, plasma protein binding, and pharmacokinetic study support.
  • Fragment-Based Lead Discovery (FBLD) Integrated fragment screening platform in partnership with SARomics Biostructures using WAC™ technology, NMR, DSF, HCS, and crystallographic methods for hit identification and validation.
  • NMR Spectroscopy Services High-quality solution NMR services ranging from quality control to advanced structure elucidation, including structural analysis of organic molecules, macrocycles, natural products, peptides, and fragment screening using ligand-detected NMR techniques.
  • Computational Chemistry

Quantifiable outcome

  • 95% sales from returning customers
  • +3 more outcomes

Companies that use RG Discovery

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

RG Discovery technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

RG Discovery partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major, strategic and minor.

  • SARomics BiostructurescoreStrategic or Co-development PartnerIntegrated fragment-based lead discovery partnership. RGD and SARomics Biostructures jointly operate the WAC fragment screening technology platform. Collaboration enables structure-based drug design throughout drug discovery phases.
  • PolyPeptidecoreStrategic or Co-development PartnerJoint project Elbe funded by Vinnova to develop sustainable manufacturing process for GLP-1 peptide without using toxic solvent DMF. Both companies contribute green chemistry expertise.
  • Cellmover ASmajorStrategic or Co-development PartnerSognefjorden project: Eurostars-funded collaboration to deliver broad checkpoint inhibitor for cancer therapy. RGD contributes macrocycle/peptide drug molecule design and development.
  • DesupervisedmajorStrategic or Co-development PartnerAId project: Eurostars-funded partnership to develop AI-based tool for drug discovery using Bayesian deep learning models for prediction of novel molecular structures.
  • Bicycle TherapeuticsstrategicStrategic or Co-development PartnerCollaboration on NMR-based structural elucidation of Zelenectide Pevedotin, a Bicycle Drug Conjugate for treatment of bladder, breast, and lung cancers.
  • Acadia PharmaceuticalsstrategicStrategic or Co-development PartnerSSRI drug discovery research collaboration for novel selective serotonin reuptake inhibitors for combination treatment with Pimavanserin.
  • ShareLabminorStrategic or Co-development PartnerPartnership to host startup competition and seminars on transforming research into drug development companies in Oslo, Norway.
  • Herantis PharmastrategicStrategic or Co-development PartnerCollaboration resulting in Nature Communications publication on CDNF neuroprotective activity and interaction with GRP78 protein.
  • ApoGlyxminorStrategic or Co-development PartnerSpinout company co-founded by RGD based on aquaporin research. RGD is co-owner. Developing RG100204 compound for sepsis treatment.
  • Zerapeutics ABminorStrategic or Co-development PartnerCompany founded in 2021 from Project Nile (epigenetic target in cancer treatment) with candidate drug development supported by Vinnova.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

RG Discovery competitors and assessment

Company assessment

Direct peers

  • BioAscent: Scotland-based CRO offering integrated drug discovery, medicinal chemistry, and compound management services to biotech and pharma clients. Comparable scale and integrated DMTA-focused service model to RG Discovery.
  • Concept Life Sciences: UK-based CRO providing integrated drug discovery including medicinal chemistry, in vitro pharmacology, ADME, and peptide chemistry. Closely comparable mid-size peer offering similar DMTA-cycle integrated services to biotech and pharma.
  • SARomics Biostructures: Swedish preclinical CRO and structural biology specialist; co-commercialises RGD's WAC fragment screening technology. Directly comparable as a Lund-based early-stage drug discovery CRO serving biotech clients with structural biology, fragment screening, and medicinal chemistry support.
  • Pelago Bioscience: Swedish CRO specialising in CETSA-based target engagement assays and cell-based biology services; acquired RG Discovery in June 2026. Now part of the same combined entity, making it the most operationally overlapping peer and the platform onto which RGD's chemistry capabilities are being bolted.
  • Sygnature Discovery: UK-based preclinical CRO offering integrated drug discovery including medicinal chemistry, in vitro biology, DMPK, and computational chemistry for biotech and pharma clients. Closely comparable in scale and service mix to RG Discovery as a fully integrated chemistry-and-biology discovery CRO.
  • Mercachem: Dutch CRO providing medicinal chemistry, custom synthesis, ADME, and parallel medicinal chemistry services to biotech and pharma. Closely comparable mid-size European peer focused on chemistry-driven integrated drug discovery.

Broad incumbents

  • Evotec: Large global contract research and discovery company offering end-to-end drug discovery, including medicinal chemistry, ADME, in vitro biology, and fragment-based screening. Overlaps directly with RGD's offerings but at significantly greater scale and with broader service portfolio.
  • Charles River Laboratories: Global CRO providing discovery and safety assessment services, including medicinal chemistry, ADME, and integrated drug discovery for pharma and biotech. Much larger incumbent competing for the same outsourced discovery spend that RGD targets.
  • Pharmaron: China/UK-headquartered CRO with integrated drug discovery and preclinical services including medicinal chemistry, in vitro biology, DMPK, and custom synthesis. Competes with RGD for biotech discovery outsourcing at much larger scale.
  • Eurofins Discovery: Discovery services arm of Eurofins Scientific offering medicinal chemistry, ADME/PK, in vitro biology, and integrated drug discovery globally. Competes with RGD for outsourced preclinical discovery but at a much larger scale across a broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

RG Discovery social profiles

Digital presence

RG Discovery compliance and trust

Trust signal

Compliance2 records

RG Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RG Discovery leadership team

Management profile

Number of profiles

Profiles10 records

RG Discovery funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RG Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RG Discovery

What does RG Discovery do?

RG Discovery is a Scandinavian contract research organization (CRO) providing premium integrated drug discovery, analysis, and custom synthesis services. The company delivers medicinal chemistry, in vitro biology/assays, ADME profiling, fragment-based lead discovery, NMR spectroscopy, computational chemistry, custom synthesis, and peptide/macrocyclic peptide services to biotechnology and pharmaceutical clients globally, with deep expertise in small molecules, peptides, and macrocycles. Services are sold via FTE-based staffing and fee-for-service engagements and supported by the proprietary WAC™ (Weak Affinity Chromatography) fragment screening platform.

Is RG Discovery a public or private company?

RG Discovery is a private company. It is classified as corporate owned and is currently acquired.

When was RG Discovery founded?

RG Discovery was founded in 2011. It employs 11 to 50 people.

Where is RG Discovery based?

RG Discovery is headquartered in Lund, Sweden, in the Europe region.

How does RG Discovery make money?

Three revenue lines are on record. Contract Research Services (FTE-based) is the primary driver. The others are fee-for-Service and custom Synthesis.

Who are RG Discovery's main competitors?

Direct peers on record are BioAscent, Concept Life Sciences, SARomics Biostructures, Pelago Bioscience, Sygnature Discovery and Mercachem. Broad incumbents are Evotec, Charles River Laboratories, Pharmaron and Eurofins Discovery.

Does RG Discovery have an API?

No public API is recorded for RG Discovery.

What industry is RG Discovery in?

RG Discovery's product category is Contract Research / Drug Discovery Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Pelago Bioscience Acquires RG Discovery To Create Integrated Drug Discovery Platform Across Biology And ChemistryPelago Bioscience announced the acquisition of RG Discovery, creating an integrated drug discovery platform that combines biology and chemistry capabilities across the full design-make-test-analyze cycle. The transaction brings together Pelago's CETSA®-based target engagement platform with RG Discovery's medicinal chemistry, custom synthesis, and ADME services, with RG Discovery employing approximately 40 scientists at its facility in Lund, Sweden. The integrated offering is designed to eliminate vendor handoffs and enable biotechnology and pharmaceutical customers to progress drug discovery programs from hit identification through lead optimization with a single provider.AijournPelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and ChemistryPelago Bioscience, a Swedish contract research organization specializing in cell-based target engagement assays, has acquired RG Discovery, another Swedish drug discovery CRO with expertise in medicinal chemistry and custom synthesis. The acquisition combines Pelago's CETSA®-based biology platform with RG Discovery's chemistry capabilities, enabling customers to access the full design-make-test-analyze cycle from a single partner without vendor handoffs. RG Discovery, founded in 2011 by former AstraZeneca scientists and employing approximately 40 scientists in Lund, will integrate into Pelago's enlarged platform.Business Wire BlogPelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and ChemistryPelago Bioscience, a Sweden-based contract research organization specializing in cell-based target engagement assays, has acquired RG Discovery, another Swedish CRO focused on medicinal chemistry and custom synthesis. The acquisition creates an integrated drug discovery platform combining Pelago's CETSA® biology technology with RG Discovery's chemistry capabilities, enabling seamless workflows from hit identification through lead optimization without vendor handoffs. RG Discovery, founded in 2011 by former AstraZeneca scientists and employing approximately 40 scientists in Lund, Sweden, will now operate as part of the enlarged Pelago group.PelagobioPelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistryPelago Bioscience acquired RG Discovery, combining its cellular target engagement assays with RG Discovery's medicinal chemistry and custom synthesis. The integrated platform enables a continuous chemistry-to-biology cycle, closing the loop from compound design to in-cell target engagement. The combined entity aims to accelerate drug discovery programs across the full design-make-test-analyze cycle.NordiclifesciencePelago Bioscience acquires RG DiscoveryPelago Bioscience acquired RG Discovery, combining its chemistry capabilities with Pelago's CETSA-based cellular thermal shift assay platform. The acquisition aims to close the loop between compound design, synthesis, and in-cell target engagement, enabling a continuous chemistry-to-biology cycle. The combined entity will offer customers a single scientific partner for drug discovery.YahooPelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and ChemistryPelago Bioscience acquired RG Discovery, combining its cellular target engagement assays with RG Discovery's medicinal chemistry and custom synthesis. The integrated platform enables a single partner to advance drug discovery from hit identification through lead optimization, closing the chemistry-to-biology loop.BioSpacePelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and ChemistryPelago Bioscience acquired RG Discovery, combining its cellular target engagement assays with RG Discovery's medicinal chemistry and custom synthesis. The integration enables a single partner to run the full design-make-test-analyze cycle, closing the loop between compound design and in-cell target engagement.